Entities / Entity
onasemnogene abeparvovec.
gene therapy product
- Reports this week
- 0
- Active events
- 0
- Connections
- 6
What's happening
No events on record for onasemnogene abeparvovec yet.
No events began in the chosen period. Widen it, or reset.
Around onasemnogene abeparvovec this week
News at the entities that move onasemnogene abeparvovec most-
Novartis StructuralNovartis acquired Avidity in a $12 billion purchase, while Trump simultaneously threatened Swiss businesses with tariffs.Moves onasemnogene abeparvovec
-
European Commission StructuralA European Commission summit focused on strategic cooperation, minerals, and pivoting away from the United States toward the EU.Moves onasemnogene abeparvovec
Connections
The 3 strongest of 6, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novartis Structural
Novartis is the company that develops, licenses, and brings the onasemnogene abeparvovec gene therapy product to market.
-
SMA Structural
Company SMA develops and offers the product onasemnogene abeparvovec as a treatment for SMA.
-
European Commission Structural
The European Commission granted regulatory approval for the product onasemnogene abeparvovec.